Fortitude Advances T-Cell Therapy for Axial Disease
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
